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electroMap: High-throughput 
open-source software for 
analysis and mapping of cardiac 
electrophysiology
Christopher o’shea1,2,3, Andrew P. Holmes1,4, Ting Y. Yu1, James Winter  1, Simon P. Wells1,11, 
Joao Correia5, Bastiaan J. Boukens6, Joris R. De Groot7, Gavin S. Chu8,9, Xin Li8, G. Andre Ng  8,9, 
paulus Kirchhof1,10, Larissa Fabritz 1,10, Kashif Rajpoot3 & Davor Pavlovic  1
The ability to record and analyse electrical behaviour across the heart using optical and electrode 
mapping has revolutionised cardiac research. However, wider uptake of these technologies is 
constrained by the lack of multi-functional and robustly characterised analysis and mapping software. 
We present ElectroMap, an adaptable, high-throughput, open-source software for processing, 
analysis and mapping of complex electrophysiology datasets from diverse experimental models and 
acquisition modalities. Key innovation is development of standalone module for quantification of 
conduction velocity, employing multiple methodologies, currently not widely available to researchers. 
electroMap has also been designed to support multiple methodologies for accurate calculation of 
activation, repolarisation, arrhythmia detection, calcium handling and beat-to-beat heterogeneity. 
ElectroMap implements automated signal segmentation, ensemble averaging and integrates 
optogenetic approaches. Here we employ ElectroMap for analysis, mapping and detection of pro-
arrhythmic phenomena in silico, in cellulo, animal model and in vivo patient datasets. We anticipate 
that ElectroMap will accelerate innovative cardiac research and enhance the uptake, application and 
interpretation of mapping technologies leading to novel approaches for arrhythmia prevention.
The incidence and prevalence of cardiac diseases continues to increase every year1,2. Adequate prevention and 
treatment requires a better understanding of the mechanistic drivers3. Detailed understanding of spatial and 
temporal electrical behaviour and ionic handling across the heart is integral to this.
Ability to measure field potentials and conduction from multiple sites can be achieved by contact/non-contact 
electrodes arrays. More recently, optical mapping has allowed measurement and mapping of action potential and 
calcium transient morphology and conduction, leading to a broader utilisation of mapping technologies in the 
cardiovascular sphere. Increasingly, electrode array mapping has made its way from pre-clinical to clinical arena 
whilst the use of optical mapping continues to expand in experimental research. Optically imaging intact tissue 
using voltage or calcium sensitive fluorescent dyes has advantages over surface electrodes but the requirement 
for contraction uncouplers and inability to perform in vivo experiments limits clinical utility of optical map-
ping4. Nevertheless, insights from optical mapping experiments have informed our understanding of complex 
arrhythmias and electrophysiological remodelling in heart disease5–8. Electrode mapping has equally provided 
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vital knowledge9,10, demonstrating that re-entry drives ventricular tachycardia11, actively guiding current clinical 
ablation strategies. Some arrhythmogenic principles, for example in atrial fibrillation (AF), remain poorly under-
stood from a mechanistic standpoint12,13 and thus require further experimentation.
Increased availability of optical mapping hardware in the laboratory has led to expansion of this technology. 
Further uptake and wider application is hindered by limitations with respect to data processing and analysis. This 
challenge is intensified as developing camera technology provides ever-increasing spatio-temporal resolution. 
Furthermore, multiple processing algorithms are employed before the underlying data can be interpreted14,15. 
These algorithms require computational expertise to implement and are commonly developed and used within 
individual research groups, utilising techniques specific to camera resolution, file type and animal species. Whilst 
some software solutions are accessible, even straightforward calculation of conduction velocity (CV) across the 
heart is currently unavailable, but to a few specialist groups. There is an unmet need for a robustly tested map-
ping software that allows high-throughput data processing, analysis, and mapping of electrophysiology from 
different acquisition modalities and diverse datasets with distinct electrophysiological (EP) properties (for exam-
ple: animal, human tissue and cell monolayers). Therefore, we present novel and robust open-source software, 
ElectroMap, for analysis of voltage and calcium optical mapping data. This work builds upon our previously pub-
lished algorithms15–17 while integrating analytic approaches developed and validated by others6,14,18,19. ElectroMap 
provides analysis of key EP parameters including action potential and calcium transient morphology, calcium 
decay constant (τ), activation and repolarisation times, diastolic interval (DI), time-to-peak, phase mapping and 
dominant frequency (DF). A key innovation is the introduction of a comprehensive CV module for robust inves-
tigation of CV changes. This module integrates established single vector18 and multi vector20 techniques for CV 
measurement as well as a novel “activation constant” analysis. Furthermore, semi-automated alternans analysis 
is enabled through development of a comprehensive alternans detection and quantification module. ElectroMap 
integrates automated pacing frequency recognition, ensemble (i.e. multi-beat) averaging and beat-to-beat analysis 
options. Here we employ ElectroMap for analysis, mapping and detection of pro-arrhythmic phenomena in silico, 
in cellulo, animal model and in vivo patient datasets, and thus demonstrate its utility for cardiac research.
Methods
Expanded details about methods are provided in the Supplementary Material. All animal procedures were under-
taken in accordance with ethical guidelines set out by the UK Animals (Scientific Procedures) Act 1986 and 
Directive 2010/63/EU of the European Parliament on the protection of animals used for scientific purposes. 
Studies conformed to the Guide for the Care and Use of Laboratory Animals published by the U.S. National 
Institutes of Health under assurance number A5634-01. Experiments were approved by the home office (mouse: 
PPL 30/2967 and PFDAAF77F, guinea pig: PPL PF75E5F7F) and the institutional review boards at University of 
Birmingham (murine) and King’s College London (guinea pig). For optical mapping of human tissue, left atrial 
appendages were obtained from patients with atrial fibrillation (AF) during thoracoscopic surgery, as described 
before21. The study was in accordance with the declaration of Helsinki and approved by the Review Board of the 
Academic Medical Center, Amsterdam. In vivo intracardiac data were obtained in a clinical study approved by 
local ethics committee for patients undergoing AF ablation at the University Hospitals of Leicester NHS Trust as 
previously described22. All patients gave written informed consent.
Optical Mapping. Both mouse and guinea pig optical mapping experiments were conducted as previously 
reported. For experiments in mouse7,15,17 fluorescent dye (Voltage: DI-4-ANEPPS, Calcium: Rhod-2AM) was 
loaded into Langendorff perfused whole hearts. Left atria were isolated, with the posterior atrial surface exposed. 
Atria were superfused under normoxic (95%O2/5%CO2) or hypoxic (95%N2/5%CO2) conditions. Pacing was per-
formed via bipolar platinum electrode, and fluorescence captured using ORCA flash 4.0 camera (1 kHz sampling 
rate, maximum field of view: 200 × 2048 pixels, 71 µm/pixel, Hamamatsu Electronics, Japan). Isolated guinea pig 
hearts8 were loaded with voltage dye Di-8-ANEPPS, paced via silver bipolar electrodes and imaged using Evolve 
Delta 512 × 512 pixel EMCCD cameras (500 Hz sampling rate, 64 × 64 pixels, 320 µm/pixel, Photometrics, USA) 
mounted on a Olympus MVX10 stereomicroscope.
Human left atrial appendages21 were removed using an endoscopic stapling device (Endo Gia stapler, Tyco 
Healthcare Group) and transported to the optical mapping setup in 100 mL cooled superfusion fluid. Atrial 
preparation was submerged in a recording chamber, loaded with Di-4-ANEPPS and paced using an epicardial 
electrode. MiCAM Ultima camera (2 kHz sampling rate, 100 × 100pixels, 100 µm/pixel SciMedia, USA) was used 
to record epicardial images.
In-vivo Human Mapping. A high-density non-contact multi-electrode array catheter (Ensite Array, St. Jude 
Medical, USA) was positioned in the right atrium. Virtual unipolar electrograms were bandpass filtered from 
1–100 Hz with additional noise filtering, then exported from a 2048 node geometry as previously described22.
ElectroMap Design and Development. All data processing and analysis was performed using 
ElectroMap, Fig. 1a. ElectroMap is developed to run on multiple platforms. It can run either within MATLAB 
or as a standalone executable (.exe for Windows and.dmg for macOS) with download of the freely available 
MATLAB runtime (see Supplementary Material). Processing parameters and additional modules are adjustable 
using custom made graphical user interfaces. Software is designed to handle the widely used TIFF and MAT 
formats. Custom input of sampling frequency and pixel size makes it compatible with various cameras and acqui-
sition systems. ElectroMap allows automatic or adjusted region selection (Fig. 1b) and multiple filtering options 
(see Supplementary Material for full details of filtering options). Unless stated otherwise, all the signals in Figs 1–
8 underwent spatial (4 × 4 pixel Gaussian, sigma = 1.5) and temporal (3rd order Savitzky-Golay) filtering to allow 
www.nature.com/scientificreports/
3Scientific RepoRts |          (2019) 9:1389  | https://doi.org/10.1038/s41598-018-38263-2
effective EP parameter quantification from single image pixels (Fig. 1c). The ElectroMap user interface permits 
signal inversion via a simple checkbox option. User-defined settings can be stored and recalled for future analysis.
Integration of automated pacing frequency recognition and numerous user-defined segmentation options 
(Supplementary Fig. I) enables simple and intuitive application of powerful analysis strategies including 
beat-to-beat analysis of long experimental files and multi-beat (ensemble) averaging to improve signal-to-noise 
ratio (SNR). Code optimization resulted in increased processing speed of up to five-times, compared to our pre-
viously published algorithms15 (Fig. 1d).
ElectroMap incorporates several definitions for activation (Start – d2F/dt2max, Upstroke – dF/dtmax, 
Depolarisation Midpoint, Peak) and repolarisation (Downstroke – dF/dtmin, Repolarization Percentage, End – 
d2F/dt2max), Supplementary Fig. II. Repolarisation percentage can be set to any custom value between 0 and 100% 
repolarisation/decay from peak for both repolarization and duration mapping (Supplementary Fig. III). Unless 
stated otherwise, depolarization midpoint was used to create activation maps, action potential duration (APD) 
was defined from upstroke to 50% repolarization and calcium transient duration (CaT) was defined from upstroke 
Figure 1. ElectroMap interface and function. (a) ElectroMap Graphical User Interface with automatic signal 
segmentation, image processing, signal processing, display and analysis options highlighted. (b) Illustration of 
4 different region selection methods available in ElectroMap. (c) Example of analysis from one pixel (top inset) 
within murine atrial images. Action potential duration (APD) 30 (blue), 50 (green) and 70 (red) are calculated 
from time of maximum upstroke velocity (vertical grey line) to 30%, 50%, 70% repolarisation respectively. Time 
of repolarisation calculated by linear interpolation (dotted line) between sampling points, as shown for 50% 
repolarisation in lower inset. (d) Time taken to process and analyse 5 image stacks of murine left atria from raw 
images to conduction velocity calculation, comparison of ElectroMap and our previously published algorithms. 
(e) Selection of pseudo-colour maps denoting some of the electrophysiological parameters measurable using 
ElectroMap.
www.nature.com/scientificreports/
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to 50% repolarization/decay. For calcium transient analysis, τ was calculated by fitting a mono-exponential model 
to a user defined region of decay from peak cytosolic calcium. Cardiac alternans were measured as change in 
duration or peak amplitude from one calcium transient to the previous. Additionally, effects of cytosolic calcium 
load were investigated by comparing ‘load’ and ‘release’ alternans amplitude, as in Wang et al.23. Analysis results 
can be exported from ElectroMap’s interface as TIFF files for individual maps, AVI/GIF files for multi-image 
analyses such as beat-to-beat (see Supplementary Video I), and comma separated value (.csv) files for parameter 
distribution and beat-to-beat analysis.
Statistical analysis. Data are presented as mean ± standard error. Differences between group means 
were examined using two-tailed, paired Student’s t-test or using One Way Analysis of Variance (ANOVA) with 
Bonferroni test, and were accepted as significant when P < 0.05.
Results
We have developed a novel, user-adaptable, semi-automated, robust, open-source software ElectroMap using 
MATLAB, see Fig. 1a for graphical user interface. The software is freely downloadable from https://github.com/
CXO531/ElectroMap, and is available as a standalone executable file or as source code which can be run and 
edited in MATLAB. Algorithms implemented within ElectroMap have previously been validated against mono-
phasic and transmembrane potentials in murine atria15. Here, we present the application and further validation of 
ElectroMap for the analysis and mapping of basic and complex cardiac electrophysiology from optical mapping 
datasets (Figs 1–8) and endocardial electrograms (Fig. 8).
Conduction Velocity Module. Analysis of the spread of electrical activation in cardiac tissue at high 
spatiotemporal resolution is one of the most powerful applications of optical mapping. We have developed a 
comprehensive CV analysis module within ElectroMap (Supplementary Fig. IV), to overcome a multitude of 
complexities and potential user-bias associated with CV calculations18,24. The module incorporates two estab-
lished methods that rely on superimposing a vector field upon the activation map: (i) multi-vector and (ii) single 
vector method (see Fig. 2a,b). Additionally, we have developed a novel method that quantifies time taken to 
activate a percentage of the tissue. This approach allows calculation of ‘activation constant’ (see Fig. 2c,d), thereby 
providing a measure of activation spread across the whole tissue.
To validate the three CV calculation methods, we generated computationally simulated model data (Fig. 3a 
and Supplementary Fig. V; for algorithms, see Supplementary Material). All three methods accurately measured 
conduction velocities ranging from 10 to 100 cm/s in isotropic model data (Fig. 3a(i)). As shown in Fig. 3b,c, 
single vector and multi-vector methods demonstrate a linear increase in CV with faster model conduction speed. 
Activation curve method accurately detected a change in CV (Fig. 3d), increase in model CV led to a reduction 
in the time taken to activate 50% (act50) of the tissue. We also validated CV analysis methods using models of ani-
sotropic activation (Fig. 3aii) and regional conduction block (Fig. 3aiii). Single vector analysis correctly detected 
slower CV along the transverse (1800/3600) compared to longitudinal (00/2700) direction in anisotropic waves, 
and conduction slowing adjacent to the region of conduction block (Fig. 3e). Similarly, multi-vector method 
successfully identified regions of reduced CV in anisotropic waves and severe conduction slowing around the 
area of conduction block (Fig. 3f). Activation curve analysis was able to detect the slowing of conduction in the 
anisotropic wave, as evident by a prolongation of the activation curve, and a delay in activation caused by con-
duction block (Fig. 3g). Additionally, Gaussian noise with incrementally increasing standard deviation (defined 
as percentage of action potential amplitude, Supplementary Fig. VII) was introduced to isotropic simulated data 
with CV of 50 cm/s, Fig. 3h. As expected, increased noise in single beat data decreases the ability to accurately 
calculate CV, with noise levels above 20% resulting in erroneous CV measurements (Fig. 3i). However, SNR can 
be improved using temporal and spatial filtering or multi-beat ensemble avenging within ElectroMap. Temporal 
filtering (Savitzky-Goaly filter) did not improve CV measurement, whereas both spatial filtering (3 × 3 Gaussian 
filter) and ensemble averaging of 10 beats substantially improved CV measurement accuracy.
Further validation was performed using experimental datasets acquired from murine left atrial tissue. We 
focused on two physiologically relevant stimuli known to reduce CV: an increase in pacing frequency25 and 
acute hypoxia26 (Fig. 4a). Indeed, significant slowing of CV, due to increased pacing frequency, was detected 
by multi-vector method (Fig. 4b, P = 0.0335) and activation curve method, as shown by an increase in the act50 
(Fig. 4c and D, P = 0.0119). Both methods also accurately detected a more severe slowing of CV caused by expo-
sure to acute hypoxia (Fig. 4e–g, P < 0.0001 and P = 0.0051 respectively).
High-Throughput Beat-to-Beat Analysis. Studies of beat-to-beat variation can provide important 
information about short periods of regional or whole tissue electrical instability, e.g. in response to pacing fre-
quency change, pharmacological agents or disease states. Therefore, we developed and tested algorithms to allow 
high-throughput analysis of beat-to-beat alterations in long experimental files. Guinea pig hearts were paced 
over 70 seconds with a 5-8-5 Hz pacing protocol27 and beat-to-beat changes in APD50 examined (Fig. 5a and 
Supplementary Videos I and II). Increasing the pacing frequency (from 5 Hz to 8 Hz) induced reversible short-
ening of mean ventricular APD (Fig. 5b). Furthermore, significant APD heterogeneity was detected in the first 4 
beats, immediately after transition from 5 Hz to 8 Hz (Fig. 5b,c). Switching back from 8 Hz to 5 Hz (at 40 s) also 
induced some APD heterogeneity while highlighting a slow return to the steady state APD (Fig. 5b,d).
Calcium Decay Mapping. Optical mapping is increasingly utilised to study calcium release patterns across 
myocardial tissue or cellular monolayers, in response to disease, genetic factors or drug administration19. The 
estimation of calcium decay constant (τ) is common in single cell studies. However, τ is not commonly mapped 
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across multicellular preparations28, likely due to lack of support for this function in available software platforms. 
We developed algorithms for calculation of CaT and τ maps, as shown in Fig. 6a,b. Importantly, CaT can be 
measured from various ‘activation times’ during upstroke (Supplementary Figs II and VI), allowing for assess-
ment of both calcium release and uptake (Fig. 6a inset). Moreover, τ can be fitted from any user-defined value 
(Fig. 6b inset). To test and validate algorithms developed for calculation of τ, mouse atria were loaded with Rhod-
2AM and paced at incremental frequencies (3-8.33-10-12.5 Hz). Software accurately calculated progressively 
shorter τ values at higher pacing frequencies (Fig. 6c,d, P < 0.0001 for all pacing frequencies compared to 3 Hz). 
Interestingly, higher pacing frequencies were associated with a reduction in τ heterogeneity (Fig. 6e, P = 0.0286 
and P = 0.0168 for 10 Hz and 12.5 Hz pacing respectively).
Alternans Analysis Module. Alternans are beat-to-beat 2-period oscillations in ion handling, electrical 
activity and hence mechanical contraction of the myocardium that can act as a precursor to conduction block and 
lethal arrhythmias29,30. We have developed a module within ElectroMap to detect and quantify alternans across 
tissue and cellular monolayers. Alternans module is capable of quantifying peak, duration, and release or load 
alternans (see Supplementary Fig. VIII for alternans definitions).
In Fig. 7 we demonstrate utility of the alternans module in detection and quantification of calcium alternans 
in a murine left atrium loaded with Rhod-2AM. The atrium was subjected to high frequency pacing of 12.5 Hz, 
initially leading to moderate alternans (Fig. 7a, blue CaTs) and then transitioning to more pronounced alternans 
(Fig. 7a, red CaTs). ElectroMap was used to generate maps allowing visualization and alternans quantification 
across the atrium (Fig. 7b,c). Alternans displayed clear spatial heterogeneity (Fig. 7b,c) with increased ‘CaT Peak 
Alternans’ correlating with changes in diastolic calcium load (‘Load Alternans’), see Fig. 7c.
Figure 2. ElectroMap conduction velocity module quantification methods. (a) Vector methods applied to 
murine atria. Top panel: multi-vector method, with local conduction vectors (arrows) calculated across the 
tissue. Lower panel: single velocity method, where conduction speed is measured along the vector (arrow) 
connecting two points. (b) Activation map represented in 3D with x,y pixel positions and activation time 
on z-axis. Upper inset demonstrates calculation of one local vector from a 5 × 5 pixel region by fitting of a 
polynomial surface (f(x,y)) to measured activation times (t(x,y)). Lower inset shows calculation of single vector 
velocity from activation time difference (Δt) and distance (r) between two selected points. (c) Activation of the 
murine atria at 20% (act20), 50% (act50), and 90% (act90), total activation. (d) The associated activation curve, 
with act20, act50 and act90 highlighted.
www.nature.com/scientificreports/
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Figure 3. Validation of conduction velocity quantification methods using model datasets. (a) Model 
conduction datasets exhibiting isotropic conduction (i), anisotropic conduction (ii) and isotropic conduction 
with a 2:1 conduction block in lower right region (iii). (b–d) Measured conduction velocities (CV) from 
isotropic conduction model datasets spanning 10 to 100 cm/s using ElectroMap. (b) CV is measured using a 
single vector from centre of sample (black) and from edge of sample (pink). (c) multi-vector method is used 
with windows sizes of 3 × 3 (green), 5 × 5 (red) and 10 × 10 (blue) pixels. CV is then measured as mean of the 
magnitude of all local vectors calculated, with error bars representing the standard deviation of the mean. (d) 
Activation curve method with act50 (time to 50% activation) used to quantify conduction. (e–g) Three CV 
quantification methods applied to model datasets with isotropic, anisotropic and conduction block present 
conduction. In all three cases, fastest model conduction was 50 cm/s. (e) Change in measured CV as a function 
of angle using single vector method from centre of tissue. (f) Distribution of local vector magnitude measured 
by multi-vector method (5 × 5 pixel window) in the three model datasets. (g) Activation curves from the model 
datasets. (h) Example activation maps from unfiltered model datasets with isotropic conduction of 50 cm/s, 
but with 10% and 30% signal noise. (i) Measured CV using multi-vector method (5 × 5 pixel window) from 
unfiltered (Black), temporally filtered (Savitzky-Golay, Blue), Spatially filtered (3 × 3 Gaussian, Green) and 10 
beat ensemble averaged (Red) model datasets at increasing noise levels, n = 5 at each noise level.
www.nature.com/scientificreports/
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Human Optical Mapping and Electrogram Recordings. ElectroMap’s utility extends to human tissue, 
see Fig. 8a for optical mapping of human atrial appendages. We also looked to test whether ElectroMap can be 
applied to analysis of clinically relevant mapping technologies. Right atrial virtual electrograms from a patient 
during sinus rhythm and AF were recorded and analysed after QRST subtraction22. During sinus rhythm, the 
spread of activation was calculated from the timing of dV/dtmin in each electrogram, generating an activation map 
(Fig. 8b). ElectroMap clearly identified higher DF components (Fig. 8c) during AF in the physiological range of 
4–10 Hz (DF range can be set within ElectroMap’s interface). Additionally, marked phase discontinuities (Fig. 8d 
and Supplementary Video III) are observed in the electrogram recordings during AF. These findings are con-
firmed using previously published algorithms22 with similar areas of high dominant frequency and discontinuous 
phase behaviour identified (Fig. 8e,f).
Additional Features. ElectroMap analysis options further extend to measure diastolic interval (DI) and 
time to peak. DI is measured from APD90 to the following activation time, which can be difficult to quantify in 
low SNR samples on a single beat. To validate the DI function, guinea pig hearts were loaded with Di-8-ANEPPS 
and pacing cycle length was decreased in 10 ms intervals from 170 ms to 110 ms. Ensemble averaging of 10 beat 
segments was used to produce an ‘average beat diastolic interval’, with improved SNR, and DI mapping function 
was validated by plotting DI-APD restitution curves (Supplementary Fig. VIII). Both APD50 and DI decrease 
more rapidly at higher pacing frequencies as previously demonstrated31.
Optogenetic excitation and pacing via light pulses in cardiac tissue expressing light sensitive ion channels is 
a novel research tool32,33 and may even be used for cardiac pacing in patients34. However, introduction of large 
amplitude light pulses will distort optical mapping images and thus preclude processing and analysis of such 
data. To this end, ElectroMap integrates a pacing artefact removal algorithm (Supplementary Fig. IX), which can 
identify and correct for light-pacing peaks, thereby allowing processing and analysis of previously obscured data.
Discussion
This work presents the development and validation of a novel open-source software for analysing and mapping 
optical and electrical signals. We demonstrate the compatibility of ElectroMap with a variety of camera types, spe-
cies and experimental models. Key features include comprehensive measurement, analysis and mapping of global 
and regional conduction, versatile signal segmentation and semi-automated high-throughput analysis of action 
potential and its spatial and temporal (beat-to-beat) variations, calcium transients, and cardiac alternans. Using 
model and real data, we demonstrate the application of ElectroMap for analysis, measurement and mapping of 
basic and complex electrophysiology and its utility in dissecting pro-arrhythmic mechanisms in vitro and in vivo.
ElectroMap is built on years of international research and development in optical mapping processing and 
analysis, described in many excellent papers and reviews6,14,15,18,35,36. Algorithms that ElectroMap relies on have 
previously been validated against monophasic and transmembrane potentials in murine atria15. Further valida-
tion performed against established open-source (Rhythm14) and commercially available software (Optiq, Cairn 
Research, UK) yielded similar APD values and activation maps (Supplementary Fig. X). To the best of our knowl-
edge, this is the first such comparison of commonly used analysis algorithms, which should help instil confidence 
Figure 4. Validation of conduction velocity quantification methods in murine atria. (a) Activation maps from 
murine atria at 3 Hz and 10 Hz pacing (i), and during normoxia and hypoxia (ii). (b) Pacing at 10 Hz slows CV, 
measured using multi-vector method. (c) Representative activation curve showing prolongation of activation 
at 10 Hz vs 3 Hz pacing. (d) Pacing at 10 Hz slows CV, measured by time to 50% activation (act50). (e) CV 
slowing induced by hypoxia, measured using multi-vector method. (f) Representative activation curve showing 
prolongation of activation curve by hypoxia. (g) Hypoxia slows CV, measured by time to 50% activation (act50). 
Grouped data displayed as mean ± standard error, n = 8, *P < 0.05 by paired t-test.
www.nature.com/scientificreports/
8Scientific RepoRts |          (2019) 9:1389  | https://doi.org/10.1038/s41598-018-38263-2
in interpretation of data generated thus far. Importantly, ElectroMap provides further functionalities and outputs, 
not widely available currently, including ensemble averaging, multiple CV methodologies, automatic frequency 
detection, signal segmentation, alternans analysis and decay constant mapping. The use of ElectroMap extends 
beyond optical mapping, allowing for its application in clinical settings with electrogram array data.
Robust validation studies performed using both model and experimental data demonstrate ElectroMap’s util-
ity for accurately quantifying key parameters of electrical function and calcium release across cardiac tissue. CV 
quantification in model data with noise verified that processing using ElectroMap allows accurate parameter 
quantification. In this case, ensemble averaging proved the most effective processing strategy due to the ran-
domness of the noise and the underlying identical morphology of all simulated action potentials. In other cir-
cumstances, (e.g. beat-to-beat variations) ensemble averaging of signals should be avoided, necessitating distinct 
processing strategies such as spatial filtering, temporal filtering and baseline correction which are all employable 
using ElectroMap.
Additionally, we demonstrate that improved processing speeds with automatic or user defined signal segmen-
tation enable more complex and computationally challenging analyses; e.g. beat-to-beat variations in APD or 
regional differences in calcium decay. Indeed, we demonstrate that using ElectroMap, rapid and straightforward 
analysis of long experimental datasets can reveal acute periods of pro-arrhythmic EP behaviour throughout the 
entire guinea pig myocardium (Fig. 5). Such analysis would otherwise be missed by ensemble averaging of multi-
ple beats or analysis of a single beat. ElectroMap, in contrast, provides rapid analysis of these complex EP parame-
ters and exports to video and spreadsheet formats that facilitate interpretation of the observed patterns. This may 
be of particular importance when examining the pathophysiological effects of rapid changes in heart rate and/
or immediate and prolonged responses to stimuli such as adrenaline or acute ischaemia. With improving SNR 
through better cameras and dyes, there is an increasing demand for beat-to-beat analysis of mapping data37,38. We 
Figure 5. Beat to beat analysis of whole guinea pig heart. (a) Tissue averaged fluorescent signal from voltage 
dye loaded guinea pig heart across 70 s experiment. (b) Graph of whole heart beat-to-beat changes in mean 
APD50. (c) Raw trace and whole heart APD50 maps prior to (beats 47 & 48) and immediately after (beats 49–
52) pacing frequency increase from 5 Hz to 8 Hz (blue in A and B). (d) Raw trace and whole heart APD50 maps 
prior to (beats 300 & 301) and immediately after (beats 302–305) pacing frequency return to 5 Hz.
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anticipate that ElectroMap’s ability to achieve such analysis in a high-throughput semi-automated manner will 
prove valuable for preclinical and clinical researchers.
The ability to simultaneously use three CV quantification methods is a key feature of ElectroMap. This is 
essential due to inherent limitations of each individual methodology for analysis of cardiac CV18,24. Here, we 
demonstrate that single vector method can suffer from significant user-generated overestimation of CV (see 
Supplementary Fig. IVA). More automated approaches have been proposed, such as that of Doshi et al.39 whereby 
single vector quantification is limited to areas where activation time linearly increases. Within ElectroMap’s con-
duction module, we have looked to overcome and highlight difficulties with the single vector method via an auto-
matic angular sweep of measured CV from a user chosen point, as in Fig. 3e and Supplementary Fig. IVA. This 
approach reveals inherent variability that stems from user-defined propagation direction. ElectroMap automat-
ically identifies the slowest conduction direction, which, in normal circumstances, will be parallel to wavefront 
propagation. The angular sweep additionally allows straightforward identification of longitudinal and transverse 
CVs40,41.
Application of multi-vector method reduces the likelihood of user-introduced errors but does not eliminate 
them completely. Simulation studies by Linnenbank et al.18 for instance demonstrate that despite increased auto-
mation, multi-vector methods can introduce systematic errors in CV quantification. The successful use of the 
method requires minimum criteria to be met in terms of grid size, local region size and angular binning for iden-
tification of propagation directions. Another problem can stem from inability to fit local vectors to some areas 
of the tissue. For example, activation definitions that are intrinsically limited to sampling rate (such as upstroke) 
can result in local regions where measured activation time is the same throughout. In such circumstances, mean-
ingful surface fit (e.g. Fig. 2b) or other methods for describing local activation such as finite difference analysis42, 
are not achievable24. This can be particularly problematic in small tissue samples, like isolated murine left atria, 
or in tissues exhibiting fast conduction and/or wavebreak. Viable solutions to this issue include interpolation of 
data between sampling points or use of alternative activation definitions such as depolarisation midpoint (see 
Supplementary Fig. II and IV). However, this relies on accurate signal interpolation, not always achievable in 
practice43. Epicardial conduction velocity quantification can also be complicated by multiple breakthroughs in 
the endocardium leading to inaccurate CV estimation during complex arrhythmias44 or in the absence of epicar-
dial pacing. In conclusion, there is no universally applicable activation measure suited for every optical mapping 
experiment, further validating the need for integration of multiple activation and CV quantification methodolo-
gies within ElectroMap.
ElectroMap incorporates a novel activation curve method of conduction analysis. This method allows 
users to quantify the time taken to activate a defined tissue percentage or study the whole activation curve. The 
Figure 6. Calcium analysis and decay constant validation. (a) CaT50 map from murine atrium as measured 
from time of maximum upstroke velocity to 50% decay, illustrated in red in region of interest signal 
(CaT50upstroke). Also shown is the measurement of CaT50 from peak amplitude in region of interest (blue, 
CaT50peak map in Supplementary Fig. VA). (b) Map of decay constant, τ, from the same atrium. Map shows 
calculation of τ by fitting of exponential decay points between 30% and 90% decay from peak (τ30–90), illustrated 
for the regional signal in blue. Also shown is calculation of τ between 10% decay and baseline (red, τ10-BL map 
in Supplementary Fig. VD). (c) Representative τ maps (τ30–90) from murine left atria as pacing frequency is 
increased. (d) Data showing shortening of mean τ across the atria with increased pacing frequency. (e) Data 
showing decrease of τ heterogeneity (measured as standard deviation of mean τ across individual atria) across 
the atria with increased pacing frequency. Data displayed as mean ± standard error, n = 5. P < 0.05, One-Way 
ANOVA followed by Bonferroni multiple comparison test against 3 Hz pacing.
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methodology is less susceptible to user bias or to sparsity of local vectors in areas of rapid conduction as it does 
not rely on user input or vector calculation. Furthermore, activation time can be normalized to tissue size, yield-
ing an activation constant in units such as ms/mm2. This extends the use of the activation constant to studies 
where tissue morphology may be altered, such as in hypertrophy or genotype dependent differences in cardiac 
structure. However, activation constant only provides a summarised measure of activation, thus a combination 
of analysis methods may be required for robust interrogation of cardiac conduction. Additionally, despite the 
various CV methods within ElectroMap, conduction analysis can remain challenging if the underlying activation 
pattern is heterogeneous, often observed in arrhythmic tissue and cultured cardiac monolayers45. The ‘Ccoffinn’ 
method of Tomek et al.24 combines sophisticated image processing techniques with novel wavefront tracking 
algorithms and can potentially overcome heterogeneity issues24.
Defining activation times for APD and CaT duration mapping is an important but complex and often poorly 
understood analysis option. Different studies utilize distinct features of the upstroke to define activation, includ-
ing dF/dtmax (upstroke)44, d2F/dt2max (start)46, depolarization midpoint47 and peak8. Similarly, time of repolari-
sation/decay can be measured at a defined repolarisation percentage15,48, dF/dtmin (downstroke) or d2F/dt2max36. 
The parameters best suited for duration measurement will depend on experimental model, signal quality and 
experimental question. We have integrated all of these user-selectable definitions within ElectroMap for both 
APD (Supplementary Fig. II) and CaT mapping (Fig. 6a and Supplementary Fig. VI).
Similarly, τ calculations can be customised in ElectroMap’s interface to calculate decay constant for any 
user-defined segment of the calcium reuptake. This permits analysis of cytosolic or SR23 calcium handling kinet-
ics in different animal species and cells. For example, note the regional discrepancy between CaT50 and τ atrial 
maps in Fig. 6a,b. This contrast results from the definition in CaT50 used, i.e. time from upstroke to 50% decay 
(CaT50upstroke). CaT50upstroke is a measure of both the release and reuptake of the cytosolic calcium. In contrast, 
τ depends only on reuptake kinetics, and so is unaffected by the changes in calcium release. By measuring CaT 
Figure 7. Alternans module. (a) Tissue averaged fluorescent signal from calcium dye loaded mouse atrium 
paced at 12.5 Hz, showing distinct alternans behaviour at 0.5–3 s (blue, moderate alternans), and 4–6.5 s (red, 
large alternans). (b) Representative signals and time averaged alternans maps from tissue during moderate 
alternans behaviour. Four maps shown correspond to the four measures of alternans available in ElectroMap 
(see methods and Supplementary Fig. VI). (c) Maps during period of large alternans (4–6.5 s) show increase in 
alternans amplitude, and clear spatial discordance.
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from peak (CaT50peak), the CaT50 and τ values become more similar across the atria (Supplementary Fig. VI). 
Deciphering pathophysiological relevance of these observations is not within the remit of this manuscript. 
However, we predict the user-defined tools for comprehensive measurement of vital duration and relaxation 
parameters that ElectroMap provides will aid understanding of cardiac pathophysiology.
The utility of processing and analysis algorithms in ElectroMap can extend beyond optical mapping. Here, we 
show analysis of in vivo virtual unipolar electrogram recordings from human right atrium (Fig. 8b–d). Despite 
the contrasting waveforms compared to optical mapping, by analysing the timing of dV/dtmin in electrogram 
recordings, ElectroMap is able to accurately calculate local activation times. Beyond its clinical utility, access to 
analyses such as dominant frequency and phase mapping, allowing mapping the site of triggered activity during 
arrhythmia (Fig. 8c,d), can aid the translation of experimental data10,49. These capabilities of ElectroMap require 
further systematic validation against a range of clinically used platforms, however current outputs are compara-
ble to previous published analysis of similar datasets22, see Fig. 8c–f. Implementation of other analysis options 
available within ElectroMap such as beat-to-beat segmentation, CV quantification and alternans detection and 
quantification hold immense potential for the analysis of electrogram data.
ElectroMap provides a robustly validated open-source flexible tool for processing and analysis of optical map-
ping data. We anticipate ElectroMap to facilitate increased uptake of optical mapping in cardiac electrophysiol-
ogy. Furthermore, application of novel data analysis strategies developed here will further our understanding of 
Figure 8. Human atrial optical and electrogram mapping analysis. (a) Activation map and example signals 
generated from human left atrial appendage stained with voltage sensitive dye. (b) Activation map and 
example signals generated from human right atrial in vivo electrogram array recordings. Labels refer to closest 
anatomical structure on 2D map - IVC and SVC: Inferior and Superior Vena Cava, CSO – Coronary Sinus 
Ostium, Fossa - Fossa Ovalis. (c) Dominant Frequency analysis between 4 and 10 Hz, showing localized area 
of increased frequency during AF. (d) Phase maps at 3 time points during sinus rhythm and AF. Synchronised 
phase behaviour during sinus rhythm is not replicated during AF. The displayed frames are taken from phase 
mapping over 30 s, Supplementary Video II. (e) Dominant Frequency analysis and (f) Phase maps at 3 time 
points during sinus rhythm and AF performed using previously published algorithms of similar datasets22.
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the mechanisms underpinning lethal arrhythmia. The application of ElectroMap extends beyond optical map-
ping. Here, we have demonstrated that ElectroMap can also be used in the analysis of clinical electrogram-based 
mapping data. Moreover, application of high-throughput CV quantification methodologies can be applied to 
drug-screening pipelines for cardiotoxic effects in cell monolayers. There is scope to broaden the existing func-
tions of ElectroMap, for example, by introducing dual-analysis of simultaneous voltage and calcium recordings 
and implementing computational approaches to overcome motion artefacts50. Furthermore, increases in compu-
tational efficiency through more sophisticated computational techniques, such as parallel processing, would allow 
for faster data processing and could eventually facilitate in-acquisition analysis.
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